New cell-based system can screen drug candidates for cardiac toxicity
A new stem cell-derived system for screening experimental drugs for cardiotoxicity could identify dangerous side effects early in the development process.
A new stem cell-derived system for screening experimental drugs for cardiotoxicity could identify dangerous side effects early in the development process, thereby potentially saving time, lives and money, according to Evan F. Cromwell, PhD, of Molecular Devices, LLC, Sunnyvale, CA, in a presentation at the American Society for Cell Biology's Annual Meeting, Dec 17 in San Francisco.
Vioxx is probably the most notorious example of a blockbuster drug removed from the market after FDA approval because of adverse cardiac side effects, Dr. Cromwell explained, but it was not the only drug to fail because of unexpected negative effects on the heart.
Cardiotoxicity remains one of the primary reasons new drugs wash out in preclinical or even full clinical trials, he said. There is often a huge cost for these failures, both to the pharmaceutical companies whose long-term investments can be wiped out in a single study and to consumers who face the risk of unintended harm.
Currently cardiotoxicity is detected using electrophysiology-based assays for interactions of compounds with potassium ion channels. However, available assays are not effective at assessing potential adverse interactions with other biochemical or contractile processes.
The need for better cardiotoxicity assays more predictive of myocardial performance led Dr. Cromwell, Oksana Sirenko, PhD, and colleagues at the California biotech, Molecular Devices, to develop an in vitro system that employs stem cell-derived cardiomyocytes to screen for potential adverse cardiac effects.
Stem cell-derived cardiomyocytes are especially suitable for an in vitro system, Dr. Cromwell explains, because they express ion channels vital for the cardiomyocytes' function and demonstrate spontaneous mechanical and electrical activity similar to that of native cardiac cells. When these cultured cardiomyocytes form a confluent layer and reach sufficient maturity, they begin to contract spontaneously. The team then employs a fast kinetic fluorescence imaging method to monitor fluctuations in intracellular calcium ion (Ca2+) levels during contractions. This provides a direct assessment of Ca2+ handling with surrogate assessments of electrophysiological activity in the muscle cell membrane and beat rate.
Phenotypic deviations from normal contractions that can be measured in the improved assay include beat rate, peak width and pattern irregularities. This multiparametric characterization of a compound's perturbation of cardiomyocyte contractions can also yield insights into mechanisms of action (MOA).
Dr. Cromwell reports, "We have characterized numerous pharmacological compounds and detected concentration-dependent modulation of beating rate and atypical patterns consistent with their MOA." This assay shows great promise to exclude preclinical candidates that have cardiotoxicity or other cardio safety issues, according to Dr. Cromwell.
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance